Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Dividend policy, buybacks, and what's happening

Feb 22, 2007 01:31PM

Feb 22, 2007 01:40PM

Feb 22, 2007 01:44PM

Feb 22, 2007 01:59PM
First off, I want to thank ttccrr7309 for his/her posts starting around #528950 ... without a doubt the best dissection of OTC financing, market manipulation and movement I have ever seen. If you're seriously day-trading, investing long term, or just fooling around, you need to understand the topics he/she discusses so ably ... to share such wisdom is just incredible; you won't get this education at Haas, Stanford, or Wharton, and if you monkey around without it, you will inevitably pay a lot for it in the "free" market. Both current data and historical perspective are needed to fathom dividend policy. Currently, it appears a single owner (through 2 entities, Swartz Private Equity and Lincoln Ventures) controls a shade less than 1/5 of the float, or around 77,000,000 shares. That certainly gets strong representation on the Board, which determines dividend policy. A $0.02 dividend payout means about $1.5million to this owner. These shares were obtained via warrants when PTSC prospects were far dimmer, at aggregate costs of around $1million. What we are seeing now is one gigantic payoff for a big boy who put his capital down when the days were pretty iffy. See referent posts above for the total take, and how it may affect your own stakes in PTSC ... whether you are long or short!!

Feb 22, 2007 02:10PM

Feb 22, 2007 02:18PM

Feb 22, 2007 03:06PM

Feb 22, 2007 03:13PM

Feb 22, 2007 03:23PM

Feb 22, 2007 03:31PM

Feb 23, 2007 09:53AM
Share
New Message
Please login to post a reply